Partnering taps into the companies’ respective strengths in clinical and preclinical urology research, enhancing the service the both firms are able to offer clients.
“UROsphere’s vast experience in investigating and validating early stage assets compliments the clinical expertise of CMX Research, providing clients with unique access to expertise across the full spectrum of drug development”, commented Philippe Lluel, CEO of UROsphere.
France-based UROsphere specialises in preclinical urogenital and renal assays. This covers testing compounds using physiological and pathological models, predicting efficacy and toxicity and proof of concept in human tissue.
Bladder, prostate and genital dysfunctions, as well as renal pathologies, are particular areas of experience and expertise at UROsphere. Services are offered as part of a full preclinical pharmacology package or on a one-off basis.
Earlier this month UROsphere strengthened its stress and mixed incontinence service offering by adding external urethral sphincter electromyography and isolated urethral tissue assay.
Companies using UROsphere for preclinical development will now have the option of continuing into clinical phases with support from Canada-based CMX Research. The partners believe this will allow clients “to efficiently move products from the bench to the bedside”.
CMX Research operates a urology network of more than 100 physicians and 120 coordinators throughout Canada. This network is used to offer project and trial management, site monitoring, data management, study design, regulatory submission and safety monitoring for Phase I to IV.
A dedicated project manager is assigned to each client to ensure communication between the sponsor, project team and investigative sites.